AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04052594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC
Study NCT03402308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Schisandra chinensis extract
Description: Schisandra chinensis extract 1,000 mg/day for 12 weeks
Study NCT03402308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch placebo 1,000 mg/day for 12 weeks
Study NCT05556213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic examination
Description: laparoscopic examination for staging of endometriosis
Study NCT05556213 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood sample to detect endometriosis
Study NCT02303821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) Methotrexate
Study NCT02303821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)
Study NCT03048591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Acupoint selection: Bilateral Hegu (LI4), Qu-chi (LI1) of upper limbs and bilateral Zusanli (ST36) ,Taichung (LR3)of lower limbs.
Study NCT00858663 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated radiation therapy
Description: All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan.
Study NCT00858663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus) + Cisplatin
Description: All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan.
Study NCT02138240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social network intervention
Description: The intervention combined a social network approach with strategies that address public housing residents' challenges related to the built environment to improve dietary habits. Given the frequent intake of sugar-sweetened beverages (SSB) in this population, the intervention focused on reducing added sugar intake through the reduced consumption of SSB.
Study NCT00475215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex solution for injection.
Study NCT00475215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium bromide solution for injection.
Study NCT02315508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUT00063
Description: 800 mg orally, once a day, for 4 weeks
Study NCT02315508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally, once a day, for 4 weeks
Study NCT00496132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO131921
Description: Escalating doses by IV infusion
Study NCT01561963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Tablets for oral administration
Study NCT01561963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin Oral Capsules
Description: Capsules for oral administration
Study NCT01561963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin IV Solution
Description: Intravenous (IV) solution
Study NCT00048750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV
Study NCT00048750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study NCT03802539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glass Liner
Description: restoration of root caries according to two different protocols
Study NCT04361890 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: perineal ultrasound
Description: all women will have ultrasound measurements of the bladder neck descent, of the movement of the ano-rectal angle during a Valsalva maneuver and elastographic measurement before and after PFMT. All measurement will be conducted by perineal route, with is a non invasive ultrasound route
Study NCT01965223 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multi-fraction SABR
Description: Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
Study NCT01965223 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Fraction SABR
Description: Single fraction SABR; 28Gy delivered in 1 fraction
Study NCT02598128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RELiZORB
Description: Peptamen 1.5 received Period A and Period B (washout only). Impact Peptide 1.5 received Period B (Days 1 and 9 only) and Period C.
Study NCT02598128 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham device
Study NCT02794389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Study NCT02794389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01930552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept AVE0005
Description: Pharmaceutical form:Solution for infusion Route of administration: Intravenous
Study NCT01930552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Pharmaceutical form:Solution for infusion Route of administration: Intravenous
Study NCT01930552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Pharmaceutical form:Solution for infusion Route of administration: Intravenous
Study NCT01930552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Pharmaceutical form:Solution for infusion Route of administration: Intravenous
Study NCT01018095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 2 gm single dose versus 7 day 500 mg BID dose
Study NCT00617955 — intervention group
Intervention type: DRUG
Intervention: Aprotinin
Description: compare outcomes of Aprotinin versus Amicar
Study NCT00617955 — intervention group
Intervention type: DRUG
Intervention: Amicar
Description: compare outcomes of Aprotinin versus Amicar
Study NCT04018313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P39
Description: 150 mg/mL, Solution for injection in PFS
Study NCT04018313 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Xolair
Description: 150 mg/mL, Solution for injection in PFS
Study NCT04018313 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Xolair
Description: 150 mg/mL, Solution for injection in PFS
Study NCT04187742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Comparison Email vs. Standard Email
Description: Evaluate whether emails with social comparison incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
Study NCT04187742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance Certification Email vs. Standard Email
Description: Evaluate whether emails with maintenance certification incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
Study NCT04187742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Report Opening Status Email vs. Standard Email (among previous report openers and non-openers)
Description: Evaluate whether emails informing physicians of their report opening status (among those who have previously opened at least one report and those who have never opened a report) will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without report opening status information
Study NCT02220114 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vigabatrin: Vigabatrin new ST formulation then Sabril®
Description: * first treatment phase (V1/D1-V3/D84), in which patients already under Sabril® granules for oral solution and naive patients start the new ST formulation; patients already under Sabril® will start at the same dose and regimen as their usual Sabril®. Dose and regimen for naive patients will be chosen according to SPC.~* second treatment phase (V3/D84-V4/D98) in which the patient is switched to Sabril® granules for oral solution (supplied by sponsor) for 15 days at the same dose as under the new ST formulation.~Dose and treatment regimen should be maintained as in first treatment phase.~- At V4/D98, patients who received Sabril® granules for oral solution (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision).
Study NCT03994315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B. infantis EVC001
Description: Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)
Study NCT03192384 — intervention group
Intervention type: BEHAVIORAL
Intervention: Educational programme
Description: Educational programme for ward staff
Study NCT03620500 — intervention group
Intervention type: BEHAVIORAL
Intervention: Gross motor and developmental balance testing
Description: Balance (Pediatric Balance Scale) and gross motor skill development (Peabody Developmental Motor Scales, 2nd edition). Quality of life will be assessed using the Life-H (Assessment of Life Habits).
Study NCT01725724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Description: Per- and postoperative transfusion of autologous salvaged blood collected with the Sangvia Blood Collection System.
Study NCT01725724 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic blood transfusion
Description: Transfusion of allogeneic blood according to the transfusion guidelines at each of the participating hospitals.
Study NCT03928249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Eriocitrin
Description: A crossover, double-blind, randomized, placebo-controlled clinical study with a duration of 26 weeks will be performed. All individuals and the principal investigator will remain blind to treatment until all analyzes are completed.~Participants will be invited to attend 12-hour fasting to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview (Appendix B) to confirm eligibility according to the inclusion and exclusion criteria . The collection of blood and the glycemic curves will be performed at the beginning of the first, 12th, 14th and 26th week in the Laboratory of Clinical Analyzes ( Araraquara)~At the beginning of the first, 12th, 14th and 26th week the following anthropometric parameters will be evaluated: body weight (kg), muscle mass (kg), fat mass (kg), body fat (%) (InBody 720, Biospace, Tokyo, Japan ) and waist-hip ratio.
Study NCT03928249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eriocitrin
Description: A crossover, double-blind, randomized, placebo-controlled clinical study with a duration of 26 weeks will be performed. All individuals and the principal investigator will remain blind to treatment until all analyzes are completed.~Participants will be invited to attend 12-hour fasting to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview (Appendix B) to confirm eligibility according to the inclusion and exclusion criteria . The collection of blood and the glycemic curves will be performed at the beginning of the first, 12th, 14th and 26th week in the Laboratory of Clinical Analyzes ( Araraquara)~At the beginning of the first, 12th, 14th and 26th week the following anthropometric parameters will be evaluated: body weight (kg), muscle mass (kg), fat mass (kg), body fat (%) (InBody 720, Biospace, Tokyo, Japan ) and waist-hip ratio.
Study NCT02194699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Tralokinumab
Description: Tralokinumab subcutaneous injection
Study NCT03994315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: B. infantis EVC001
Description: Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)
Study NCT03994315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lacto-N-tetraose (LNT)
Description: LNT is a human milk oligosaccharide (HMO) found in human breast milk and is a selective prebiotic for B. infantis.
Study NCT00724906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123 I - ALTROPANE®
Description: 8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.
Study NCT02303821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Study NCT02303821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02303821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02303821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Study NCT01670617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Particulated Juvenile Articular Cartilage
Description: Treatment of articular cartilage defects up to 7.5 cm2
Study NCT00970827 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic postconditioning
Description: Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).
Study NCT00970827 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: remote ischemic postconditioning
Description: Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).
Study NCT03536611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran
Description: dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
Study NCT03536611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
Study NCT01998841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab
Description: Crenezumab will be administered as per the schedule specified in the treatment arm.
Study NCT01998841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the schedule specified in the treatment arm.
Study NCT01056289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine Succinate Sustained-Release Formulation 50 mg
Description: DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
Study NCT01056289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine Succinate Sustained-Release Formulation 25 mg
Description: DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
Study NCT01056289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
Study NCT04604340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transradial access for neuroangiography
Description: The choice of right vs left radial artery approach would be determined by the vessels that require the highest quality of imaging (e.g. if the left vertebral artery is key to diagnosis, a left radial approach would be chosen, otherwise a right radial approach would be likely most appropriate) - this decision is at the discretion of the interventionist.
Study NCT04604340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transfemoral access for neuroangiography
Description: By convention, femoral access will be obtained on the right side, unless there is overlying disease or vessel abnormality detected by ultrasound/Doppler, as is usual clinical practice.
Study NCT04952818 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RANK/RANKL(RANK: Receptor Activator of Nuclear factor Kappa-Β /RANKL:Receptor Activator of Nuclear factor Kappa-Β Ligand)
Description: Immunohistochemical staining was performed using the following antibodies: anti-RANK antibody from Bioss Company (No.bs-2695R) and anti-RANKL antibody from Abcam (No.ab222215).
Study NCT01653717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Blood drawn through a needle in a vein in one arm, then passed though a machine to collect white blood cells, and then remaining blood returned back to patient through a needle in a vein in other arm. Procedure will take about 3 hours to complete.
Study NCT01653717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 by vein on Days -5 to Day -3.
Study NCT01653717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/kg by vein on Days -5 to -3.
Study NCT01653717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-cell Infusion
Description: Beginning dose of genetically modified cells is > 5x10\^7/m2 but less than or equal to 5 x10\^8/m2 infused on Day 0.
Study NCT03544944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJP-008-1
Description: Subjects who are randomized into group TJP-008-1 will receive bowel preparation on the same-day.
Study NCT03544944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJP-008-2
Description: Subjects who are randomized into group TJP-008-2 will receive bowel preparation from evening to next morning.
Study NCT03544944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coolprep powder
Description: Subjects who are randomized into group Coolprep will receive bowel preparation from evening to next morning.
Study NCT05937737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes Diet Modification
Description: A 12-week dietary intervention model was prescribed to the patients in accordance with their needs.
Study NCT01476514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: The testing will be the same for healthy volunteers and patients with a mutations in the glycine channel.
Study NCT03619265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prickly pear juice
Description: 3 ounces daily for 8 weeks.
Study NCT03619265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pear-flavored juice
Description: 3 ounces daily for 8 weeks.
Study NCT02128672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulator Lead Placement
Study NCT02128672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator Lead Placement
Study NCT01044121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mattress Firmness
Description: Current mattress and 6 experimental firmnesses of mattress as defined by a Comfort Support Analysis device.
Study NCT01708551 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT01027195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bipolar Radiofrequency (Aquamantys 6.0)
Study NCT01027195 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Bovie Electrocautery